Literature DB >> 21293088

Long-term blood pressure control: what can we do?

Joel M Neutel1.   

Abstract

There are unique problems associated with the long-term control of blood pressure (BP) in patients with hypertension. Many of these problems warrant specific discussion for the primary care physician. Up to one-third of high-risk patients are estimated to have uncontrolled hypertension. Although long-term control is essential to avoid complications of cardiovascular disease, such as myocardial infarction, stroke, heart failure, and kidney disease, it can become troublesome because of challenges with patient compliance and adherence to medication regimens. This may be due to low tolerability profiles, complicated regimens, or prohibitive costs. Trials have shown that a combination approach may reduce side effects with complementary therapies such as a calcium channel blocker (CCB)/angiotensin receptor blocker (ARB) combination. Combination therapy can be used in any patient group not responsive to monotherapy, or who remain 20 mm Hg higher than their BP goal. This method may achieve the goal of reaching target BP sooner as a first-line approach and, in a fixed-dose combination, may be a more economic choice as well as a simpler regimen for the patient. Together with supportive measures, CCB/ARB combinations are a compelling alternative for the long-term treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21293088     DOI: 10.3810/pgm.2011.01.2249

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  3 in total

1.  How many hypertensive patients can be controlled in "real life": an improvement strategy in primary care.

Authors:  Alessandro Filippi; Diego Sangiorgi; Stefano Buda; Luca Degli Esposti; Giulio Nati; Italo Paolini; Antonino Di Guardo
Journal:  BMC Fam Pract       Date:  2013-12-13       Impact factor: 2.497

2.  Efficacy and tolerability of a single-pill combination of telmisartan 80 mg and hydrochlorothiazide 25 mg according to age, gender, race, hypertension severity, and previous antihypertensive use: planned analyses of a randomized trial.

Authors:  Dingliang Zhu; Harold Bays; Pingjin Gao; Michaela Mattheus; Birgit Voelker; Luis M Ruilope
Journal:  Integr Blood Press Control       Date:  2013-04-03

3.  Diltiazem reduces mortality and breakdown of ATP in red blood cell induced by isoproterenol in a freely moving rat model in vivo.

Authors:  Pollen K F Yeung; Zhaolin Xu; Dena Seeto
Journal:  Metabolites       Date:  2014-09-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.